All patients
adolescents (typically 12-15 years of age) adults (typically between 18 and 65yr) age >= 55 yr age >= 60 yr age >= 65 yr age >= 75 yr alpha variant (B.1.1.7, UK) any cancer autoimmune disease beta variant (B.1.351 / 501Y.V2, South Africa) children corticosteroids: no corticosteroids: yes critical disease delta variant (B.1.617.2, Indian) dialysis patients elderly (typically over 65yr) fully vaccinated gamma variant (P.1, Brazil) haematological cancers healthcare workers immunodepression invasive ventilation kidney transplant recipients no oxygen needed non invasive oxygen obese omicron variant BA.1 (B.1.1.529) omicron variant BA.2 VOC original (Wuhan) strain positive for SARS-Cov-2 at baseline severe disease solid cancer solid organ transplant recipients subjects at risk
potential COVID-19 treatments in COVID 19 outpatients - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias Emergency room visit or hospitalizationdetailed results ACTIV-6, 2022 1.10 [0.64; 1.91]
ACTIV-6 (ivermectine), 2023 0.94 [0.58; 1.53]
COVID-OUT (fluvoxamine), 2022 1.17 [0.57; 2.40]
COVID-OUT (ivermectin), 2022 1.39 [0.72; 2.69]
1.10 [0.82 ; 1.47 ] ACTIV-6, 2022, ACTIV-6 (ivermectine), 2023, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022 4 0% 2,659 low not evaluable death D28detailed results EPIC-HR, 2021 0.04 [0.00; 0.70]
Fischer (all doses), 2021 0.22 [0.01; 6.60]
MOVe-OUT, 2021 0.06 [0.00; 1.05]
PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30]
TOGETHER, 2021 0.69 [0.37; 1.30]
0.28 [0.07 ; 1.04 ] EPIC-HR, 2021, Fischer (all doses), 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, TOGETHER, 2021 5 37% 5,108 moderate not evaluable deathsdetailed results ACTIV-6 (ivermectine), 2023 2.01 [0.07; 59.98]
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 1.15 [0.02; 58.61]
COPE – Coalition V, 2022 1.56 [0.39; 6.24]
COVID-PEP Severity (Skipper), 2020 1.01 [0.06; 16.28]
EPIC-HR, 2021 0.04 [0.00; 0.70]
Fischer (all doses), 2021 0.22 [0.01; 6.60]
IVERCORCOVID19 (Vallejos), 2020 1.34 [0.30; 6.03]
Lopez-Medina, 2021 0.50 [0.02; 14.95]
MOVe-OUT, 2021 0.06 [0.00; 1.05]
PATCH Cohort 1 (Amaravadi), 2021 0.86 [0.02; 46.71]
PINETREE (GS-US-540-9012), 2021 1.01 [0.02; 51.30]
PRINCIPLE, 2021 1.65 [0.03; 83.12]
Reis (Hydroxychloroquine) (TOGETHER), 2021 0.26 [0.01; 5.88]
TOGETHER, 2021 0.80 [0.43; 1.50]
TOGETHER (ivermectine), 2022 0.87 [0.48; 1.58]
0.81 [0.56 ; 1.17 ] ACTIV-6 (ivermectine), 2023, BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, COPE – Coalition V, 2022, COVID-PEP Severity (Skipper), 2020, EPIC-HR, 2021, Fischer (all doses), 2021, IVERCORCOVID19 (Vallejos), 2020, Lopez-Medina, 2021, MOVe-OUT, 2021, PATCH Cohort 1 (Amaravadi), 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, Reis (Hydroxychloroquine) (TOGETHER), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022 15 0% 12,493 low low deaths (time to event analysis only)detailed results TOGETHER, 2021 0.80 [0.43; 1.50]
0.80 [0.43 ; 1.50 ] TOGETHER, 2021 1 0% 1,472 NA not evaluable hospitalization or deathdetailed results ACTIV 6 ivermectin, 2022 1.05 [0.43; 2.61]
ALBERTA HOPE-Covid19, 2021 2.73 [0.14; 52.87]
COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75]
COVID-OUT (ivermectin), 2022 0.73 [0.19; 2.79]
EPIC-HR, 2021 0.12 [0.06; 0.24]
Hinks (ATOMIC2), 2021 0.91 [0.43; 1.92]
IVERCORCOVID19 (Vallejos), 2020 0.66 [0.33; 1.30]
MOVe-OUT, 2021 0.48 [0.30; 0.78]
PINETREE (GS-US-540-9012), 2021 0.13 [0.03; 0.58]
TOGETHER, 2021 0.76 [0.57; 1.02]
0.56 [0.35 ; 0.89 ] ACTIV 6 ivermectin, 2022, ALBERTA HOPE-Covid19, 2021, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, EPIC-HR, 2021, Hinks (ATOMIC2), 2021, IVERCORCOVID19 (Vallejos), 2020, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, TOGETHER, 2021 10 71% 8,891 low low A EFFACER PCR-negative (end of follow-up)detailed results Hinks (ATOMIC2), 2021 0.91 [0.57; 1.46]
0.91 [0.57 ; 1.46 ] Hinks (ATOMIC2), 2021 1 0% 295 NA not evaluable clinical deteriorationdetailed results COVID-OUT (fluvoxamine), 2022 0.94 [0.65; 1.35]
COVID-OUT (ivermectin), 2022 1.05 [0.76; 1.45]
Lenze (STOP COVID 1), 2020 0.07 [0.00; 1.26]
Lopez-Medina, 2021 0.56 [0.16; 1.95]
PATCH Cohort 1 (Amaravadi), 2021 0.51 [0.07; 3.68]
TOGETHER, 2021 0.64 [0.47; 0.87]
TOGETHER (ivermectine), 2022 0.90 [0.70; 1.16]
0.84 [0.68 ; 1.03 ] COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, Lenze (STOP COVID 1), 2020, Lopez-Medina, 2021, PATCH Cohort 1 (Amaravadi), 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022 7 34% 4,883 moderate not evaluable clinical improvementdetailed results ACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18]
COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11]
Lopez-Medina, 2021 1.07 [0.87; 1.32]
PRINCIPLE, 2021 1.08 [0.95; 1.23]
1.08 [1.00 ; 1.16 ] ACTIV 6 ivermectin, 2022, COVID-PEP Severity (Skipper), 2020, Lopez-Medina, 2021, PRINCIPLE, 2021 4 0% 3,709 low not evaluable clinical improvement (14-day)detailed results ACTION, 2021 1.01 [0.75; 1.37]
COVID-PEP Severity (Skipper), 2020 1.36 [0.87; 2.11]
1.12 [0.85 ; 1.47 ] ACTION, 2021, COVID-PEP Severity (Skipper), 2020 2 13% 658 moderate not evaluable clinical improvement (21-day)detailed results Lopez-Medina, 2021 1.28 [0.79; 2.10]
1.28 [0.79 ; 2.10 ] Lopez-Medina, 2021 1 0% 400 NA not evaluable clinical improvement (28-day)detailed results ACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18]
1.07 [0.97 ; 1.18 ] ACTIV 6 ivermectin, 2022 1 0% 1,591 NA not evaluable clinical improvement (time to event analysis only)detailed results ACTIV 6 ivermectin, 2022 1.07 [0.97; 1.18]
Lopez-Medina, 2021 1.07 [0.87; 1.32]
PRINCIPLE, 2021 1.08 [0.95; 1.23]
1.07 [1.00 ; 1.16 ] ACTIV 6 ivermectin, 2022, Lopez-Medina, 2021, PRINCIPLE, 2021 3 0% 3,314 low not evaluable hospitalizationdetailed results ACTIV-6, 2022 0.45 [0.04; 5.03]
ACTIV-6 (ivermectine), 2023 2.01 [0.37; 11.03]
BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 0.75 [0.32; 1.76]
Buonfrate (COVER-HIGH DOSE ARM C), 2022 6.33 [0.30; 132.38]
COPE – Coalition V, 2022 0.77 [0.52; 1.13]
COVID-OUT (fluvoxamine), 2022 1.11 [0.33; 3.75]
COVID-OUT (ivermectin), 2022 0.73 [0.19; 2.79]
Hinks (ATOMIC2), 2021 0.95 [0.46; 1.96]
IVERCORCOVID19 (Vallejos), 2020 0.65 [0.32; 1.32]
MOVe-OUT, 2021 0.49 [0.30; 0.79]
PATCH Cohort 1 (Amaravadi), 2021 1.79 [0.06; 57.93]
PINETREE (GS-US-540-9012), 2021 0.28 [0.10; 0.77]
PRINCIPLE, 2021 0.94 [0.50; 1.75]
Reis (Hydroxychloroquine) (TOGETHER), 2021 0.76 [0.30; 1.90]
Rodrigues, 2021 2.02 [0.07; 62.02]
Roozbeh, 2020 0.23 [0.02; 2.21]
TOGETHER, 2021 0.76 [0.57; 1.02]
TOGETHER (ivermectine), 2022 0.81 [0.59; 1.11]
0.75 [0.64 ; 0.87 ] ACTIV-6, 2022, ACTIV-6 (ivermectine), 2023, BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Buonfrate (COVER-HIGH DOSE ARM C), 2022, COPE – Coalition V, 2022, COVID-OUT (fluvoxamine), 2022, COVID-OUT (ivermectin), 2022, Hinks (ATOMIC2), 2021, IVERCORCOVID19 (Vallejos), 2020, MOVe-OUT, 2021, PATCH Cohort 1 (Amaravadi), 2021, PINETREE (GS-US-540-9012), 2021, PRINCIPLE, 2021, Reis (Hydroxychloroquine) (TOGETHER), 2021, Rodrigues, 2021, Roozbeh, 2020, TOGETHER, 2021, TOGETHER (ivermectine), 2022 18 0% 12,578 moderate low mechanical ventilationdetailed results COPE – Coalition V, 2022 1.32 [0.46; 3.79]
IVERCORCOVID19 (Vallejos), 2020 1.34 [0.30; 6.03]
PRINCIPLE, 2021 0.50 [0.10; 2.60]
1.08 [0.50 ; 2.31 ] COPE – Coalition V, 2022, IVERCORCOVID19 (Vallejos), 2020, PRINCIPLE, 2021 3 0% 2,991 moderate not evaluable Recovery (time to event analysis only)detailed results ACTIV-6 (ivermectine), 2023 1.02 [0.92; 1.13]
Buonfrate (COVER-HIGH DOSE ARM C), 2022 0.79 [0.42; 1.48]
1.01 [0.92 ; 1.12 ] ACTIV-6 (ivermectine), 2023, Buonfrate (COVER-HIGH DOSE ARM C), 2022 2 0% 1,270 low not evaluable viral clearance detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Fischer (all doses), 2021 14.50 [1.70; 123.69]
Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61]
Reis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03]
Rodrigues, 2021 1.00 [0.42; 2.39]
TOGETHER, 2021 0.67 [0.42; 1.06]
0.90 [0.76 ; 1.07 ] Chaccour, 2020, Fischer (all doses), 2021, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Reis (Hydroxychloroquine) (TOGETHER), 2021, Rodrigues, 2021, TOGETHER, 2021 6 39% 1,386 moderate not evaluable viral clearance by day 14detailed results IVERCORCOVID19 (Vallejos), 2020 0.76 [0.45; 1.28]
Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.55 [0.32; 0.94]
Reis (Hydroxychloroquine) (TOGETHER), 2021 0.92 [0.82; 1.03]
0.79 [0.59 ; 1.07 ] IVERCORCOVID19 (Vallejos), 2020, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Reis (Hydroxychloroquine) (TOGETHER), 2021 3 48% 1,173 moderate not evaluable viral clearance by day 7detailed results Chaccour, 2020 0.92 [0.77; 1.09]
Fischer (all doses), 2021 14.50 [1.70; 123.69]
Q-PROTECT (HCQ/AZI vs PLACEBO), 2020 0.86 [0.46; 1.61]
Rodrigues, 2021 1.00 [0.42; 2.39]
TOGETHER, 2021 0.67 [0.42; 1.06]
TOGETHER (ivermectine), 2022 0.99 [0.59; 1.67]
0.91 [0.69 ; 1.20 ] Chaccour, 2020, Fischer (all doses), 2021, Q-PROTECT (HCQ/AZI vs PLACEBO), 2020, Rodrigues, 2021, TOGETHER, 2021, TOGETHER (ivermectine), 2022 6 40% 1,313 low not evaluable emergency room observation for > 6 hours or hospitalizationdetailed results TOGETHER, 2021 0.64 [0.47; 0.87]
0.64 [0.47 ; 0.87 ] TOGETHER, 2021 1 0% 1,497 NA not evaluable ICU admissiondetailed results COPE – Coalition V, 2022 0.84 [0.43; 1.63]
PRINCIPLE, 2021 0.76 [0.18; 3.18]
0.82 [0.45 ; 1.50 ] COPE – Coalition V, 2022, PRINCIPLE, 2021 2 0% 2,489 moderate not evaluable recoverydetailed results ACTIV-6, 2022 0.96 [0.86; 1.07]
0.96 [0.86 ; 1.07 ] ACTIV-6, 2022 1 0% NA not evaluable AE leading to drug discontinuationdetailed results Fischer (all doses), 2021 0.88 [0.08; 9.94]
MOVe-OUT, 2021 0.49 [0.23; 1.05]
PINETREE (GS-US-540-9012), 2021 0.40 [0.08; 2.09]
TOGETHER, 2021 1.38 [0.98; 1.95]
0.79 [0.37 ; 1.69 ] Fischer (all doses), 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021, TOGETHER, 2021 4 60% 3,672 moderate not evaluable related AE (TRAE)detailed results EPIC-HR, 2021 1.76 [1.10; 2.82]
1.76 [1.10 ; 2.82 ] EPIC-HR, 2021 1 0% 1,349 NA not evaluable related SAE (TRSAE)detailed results EPIC-HR, 2021 1.01 [0.25; 4.05]
1.01 [0.25 ; 4.05 ] EPIC-HR, 2021 1 0% 1,349 NA not evaluable serious adverse eventsdetailed results Fischer (all doses), 2021 1.34 [0.14; 13.10]
Lenze (STOP COVID 1), 2020 0.17 [0.02; 1.49]
Lopez-Medina, 2021 1.00 [0.14; 7.17]
MOVe-OUT, 2021 0.70 [0.48; 1.03]
PINETREE (GS-US-540-9012), 2021 0.25 [0.09; 0.69]
0.53 [0.29 ; 0.98 ] Fischer (all doses), 2021, Lenze (STOP COVID 1), 2020, Lopez-Medina, 2021, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021 5 27% 2,727 low not evaluable adverse eventsdetailed results BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020 178.20 [73.71; 430.85]
Chaccour, 2020 1.00 [0.20; 5.07]
COVID-PEP Severity (Skipper), 2020 2.75 [1.80; 4.21]
Fischer (all doses), 2021 1.05 [0.54; 2.02]
Lenze (STOP COVID 1), 2020 0.98 [0.40; 2.38]
MOVe-OUT, 2021 0.89 [0.71; 1.11]
PINETREE (GS-US-540-9012), 2021 0.85 [0.61; 1.19]
2.31 [0.92 ; 5.82 ] BCN PEP-CoV-2-Study 2 (Mitja et al. Clin Infect Dis), 2020, Chaccour, 2020, COVID-PEP Severity (Skipper), 2020, Fischer (all doses), 2021, Lenze (STOP COVID 1), 2020, MOVe-OUT, 2021, PINETREE (GS-US-540-9012), 2021 7 96% 3,127 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-08 07:17 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 97
- treatments: 290,547,608,830,831,829,901,680,595,828,681,1209,833,629,689,543,617,625,859,511,960,546,564,944,682,1266,943,894,560,1102,598,563,668,753,752,836,639,541,534,581,615,679,522,582,666,1149,1150,737,544,733,597,524,611,538,957,958,521,566,517,881,904,882,897,896,899,1235,898,687,740,883,947,536,591,729,887,742,878,975,570,771,888,1141,690,880,1255,567,596,1437,600,652,557,635,1236,553,628,646,645,607,395,920,1438,927,932,931,1263,599,614,942,1436,928,923,535,1046,727,818,606,954,964,962,963,1045,638,677,627,533,526,616,926,1246,726,580,568,527,588,539,585,691,1210,525,843,827,1047,1048,819,545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814,649,650,589,651,968,1245,610,751,747,695,548,970,594,565,879,1257,571,626,697,572,1234,586,573,540,592,930,949,838,698,934,735,929,948,946,945,587,655,1146,531,933,613,919,725,678,921,621,959,748,1348,1256,924,1243,925,658,699,612,552,590,891,605,892,722,618,609,551,834,763,922,935,620,1317,1265,824,766,857,1291,1088,1331,1330,1329,1344,1328,1327,979,822,762,805,950,757,761,806,758,826,755,821,1288,1287,1286,760,1284,802,765,1285,759,823,804,1264,764,858,835,1262,1290,1316,1341,1342,1343,825,803,1244,523,885,734,1439
- roots T: 290